SwiftScale speeds up the manufacture of COVID-19 antibodies

By The Science Advisory Board staff writers

June 9, 2020 -- SwiftScale Biologics said it has used its rapid biologics manufacturing platform to manufacture a COVID-19 neutralizing antibody candidate at clinical scale.

Designed to reduce biologics development time by several months in comparison with traditional manufacturing platforms, SwiftScale's platform leverages synthetic biology techniques and unique strains to produce high yields of therapeutics in their physiological and functional forms at large scale, according to the firm. SwiftScale said that it's in the process of reaching a production capacity of 100,000 doses per month under good manufacturing practices specifications.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.